We became interested in PEDF as a potential treatment in ROP because it is neuroprotective [25] and anti-inflammatory [36], potentially may regulate VEGF-induced pathologic angiogenesis, and has been safely tolerated in a human clinical trial [31]. This evidence concerns the gene VEGFA and retinopathy of prematurity.